05/27/22 3:27 PMNasdaq : VRCA low floatKirby McInerney LLP Announces an Investigation of Shareholder Claims on Behalf of Verrica Pharmaceuticals Inc. (VRCA) InvestorsThe law firm of Kirby McInerney LLP is investigating potential claims against Verrica Pharmaceuticals Inc.. If you purchased or otherwise acquired Verrica securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this...RHEA-AIvery negative
05/24/22 8:00 PMNasdaq : VRCA low floatVerrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLCVerrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations Review Division had advised Verrica that the review of NDA was completed and label was ready to be communicated, except forRHEA-AIneutral
05/09/22 7:30 AMNasdaq : VRCA earningslow floatVerrica Pharmaceuticals Reports First Quarter 2022 Financial ResultsVerrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics companyRHEA-AIneutral
04/07/22 7:30 AMNasdaq : VRCA low floatVerrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare ConferenceVerrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participateRHEA-AIneutral
04/05/22 7:30 AMNasdaq : VRCA clinical triallow floatVerrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell CarcinomaLTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatmentRHEA-AIneutral
03/02/22 4:05 PMNasdaq : VRCA earningslow floatVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial ResultsVerrica Pharmaceuticals Inc. (Verrica)RHEA-AIneutral
02/24/22 7:30 AMNasdaq : VRCA low floatVerrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare ConferenceVerrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, will participate inRHEA-AIneutral
12/15/21 4:05 PMNasdaq : VRCA low floatVerrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum ContagiosumVerrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (FDA) acknowledgedRHEA-AIvery positive
11/29/21 7:30 AMNasdaq : VRCA low floatVerrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum ContagiosumVerrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application (NDA) forRHEA-AIneutral
11/18/21 7:30 AMNasdaq : VRCA low floatVerrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell CarcinomaVerrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:RHEA-AIneutral